Paper Details

  1. Home
  2. Paper Details

Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children.

Author: ChartrandCaroline, ChauhanBhupendrasinh F, DucharmeFrancine M, MilanStephen J, Ni ChroininMuireann

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Adding a long-acting beta2-agonist (LABA) to an inhaled corticosteroid (ICS) in children and adolescents with asthma did not significantly reduce exacerbations requiring oral steroids, but improved lung function compared to higher doses of ICS alone. There were no significant differences in adverse effects, except for greater growth with LABA plus ICS than with higher ICS doses.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Long-acting beta2-agonists (LABA) in combination with inhaled corticosteroids (ICS) are increasingly prescribed for children with asthma. OBJECTIVES: To assess the safety and efficacy of adding a LABA to an ICS in children and adolescents with asthma. To determine whether the benefit of...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426997/

データ提供：米国国立医学図書館（NLM）

Long-Acting Beta2-Agonists for Asthma in Children

Asthma, a chronic lung condition, can be as unpredictable as a desert sandstorm. This study examines the use of long-acting beta2-agonists (LABA) in combination with inhaled corticosteroids (ICS) for children with asthma, aiming to find a safe and effective treatment strategy.

The study included 33 trials, representing 39 control-intervention comparisons, and involved a total of 6381 children. The main outcome measure was the rate of asthma exacerbations requiring rescue oral steroids. The results show that adding LABA to ICS did not significantly reduce the rate of exacerbations, but it was superior to ICS alone in improving lung function. Importantly, the study found no difference in adverse effects between the two treatment groups, except for a greater growth rate with the combination therapy compared to higher ICS doses.

LABA and ICS: A Balanced Approach for Asthma Management

While LABA and ICS combination therapy did not significantly reduce the number of asthma exacerbations, it did improve lung function in children with persistent asthma. This suggests that LABA and ICS might be a valuable tool for managing asthma in children, but further research is needed to understand the long-term implications of LABA use in this population.

Considerations for Children with Asthma

This study emphasizes the importance of finding the right treatment strategy for children with asthma. While the combination of LABA and ICS might be beneficial for improving lung function, the lack of significant reduction in exacerbations raises concerns about the long-term risks and benefits of this approach. Parents and healthcare providers should carefully consider the individual needs of each child and weigh the potential benefits against potential risks before deciding on a treatment plan.

Dr.Camel's Conclusion

This study is like navigating a challenging desert terrain. While we see the benefits of LABA and ICS combination therapy in improving lung function, the lack of improvement in reducing exacerbations requires further exploration. Finding the right balance between treatment effectiveness and potential risks is crucial for the well-being of children with asthma.

Date :
  1. Date Completed 2016-03-30
  2. Date Revised 2022-09-02
Further Info :

Pubmed ID

26594816

DOI: Digital Object Identifier

PMC9426997

Related Literature

Article Analysis
・Effects of beclomethasone oral inhalation
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.